$ANAB

$49.32▲ +5.7% YTD

4 SEC 13D/G filings tracked · Last updated Oct 19, 2026

Filing History

CP $49.32▲ +5.7%Oct 19, 2026 · ThinkSabio Blog

$ANAB - Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer…

News

ANAB ▼ -0.5% - AnaptysBio, Inc.

CP $54.92▲ -0.5%Sep 21, 2026 · ThinkSabio Blog

$ANAB - Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update…

News

ANAB ▼ -2.9% - AnaptysBio, Inc.

CP $55.28▲ -2.9%Sep 1, 2026 · ThinkSabio Blog

$ANAB - Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference…

SEC 13D/G

ANAB - AnaptysBio, Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks Simplified

$55.90▲ 24.17%Aug 14, 2026 · ThinkSabio Blog

$ANAB SEC 13D/G institutional ownership filing. Healthcare sector. SEC Filing Update: #ANAB AnaptysBio, Inc. : $55.90 Sector: Healthcare | YTD: 🔼+ 24…